logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Says Lung Cancer Trial Data Erroneous - Quick Facts

Peregrine Pharmaceuticals Inc. (PPHM) announced that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments.

The company stated that due to the double-blind nature of the trial, it was not permitted to have access to either patient group assignments or related product coding information.

As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After reporting a modest improvement in U.S. consumer confidence in the previous month, the Conference Board released a report on Tuesday showing that its consumer confidence index increased by much more than expected in June. While MNI Indicators released a report on Tuesday showing a notable increase by its Chicago business barometer in the month of June, the index continued to point to a contraction in regional business activity. It was nice while it lasted, but the days of free checked luggage are nearly almost over. JetBlue is hitting its lowest-fare customers with a $20 checked bag fee per one-way trip.
comments powered by Disqus
Follow RTT